Edition:
United States

Swedish Orphan Biovitrum AB (publ) (SOBIV.ST)

SOBIV.ST on Stockholm Stock Exchange

186.95SEK
4:47am EST
Change (% chg)

1.00kr (+0.54%)
Prev Close
185.95kr
Open
190.00kr
Day's High
190.95kr
Day's Low
186.60kr
Volume
159,845
Avg. Vol
970,281
52-wk High
299.60kr
52-wk Low
108.90kr

Select another date:

Tue, Nov 20 2018

BRIEF-FDA Approves Gamifant For Primary Hemophagocytic Lymphohistiocytosis

* FDA APPROVES GAMIFANT® (EMAPALUMAB-LZSG), THE FIRST AND ONLY TREATMENT INDICATED FOR PRIMARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH)

CORRECTED-Sweden's Sobi buys rights for emapalumab drug, strengthening inflammation business

STOCKHOLM, July 20 Drugmaker Swedish Orphan Biovitrum (Sobi) said on Friday it had reached an exclusive licensing deal with Swiss firm Novimmune SA for the perpetual global rights to emapalumab, a late-stage orphan drug candidate for the treatment of primary Haemophagocytic lymphohistiocytosis.

Select another date: